SCHEMBL31087828

SCHEMBL31087828

CC=CC=CC=CC(=O)CCC=CC=CC=CC=CCC

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
OXER1 Q8TDS5 4/20 0.45
CNR2 P34972 9/20 0.44
CNR1 P21554 7/20 0.44
KDM4E B2RXH2 1/20 0.44
PPARA Q07869 3/20 0.42
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
TRPA1 O75762 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
ALOX12 P18054 2/20 0.38
SOAT1 P35610 1/20 0.37
ALOX5 P09917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31626860 0.79 OXER1 (0.45) OXER1CNR2CNR1KDM4EPPARA
SCHEMBL3007779 0.77 TRPA1 (0.45) OXER1CNR2CNR1KDM4ETRPA1
SCHEMBL3004060 0.77 TRPA1 (0.45) OXER1CNR2CNR1KDM4ETRPA1
SCHEMBL9222284 0.77 ALDH1A1 (0.42) OXER1CNR1KDM4EPPARAPPARG
SCHEMBL9222289 0.77 ALDH1A1 (0.42) OXER1CNR1KDM4EPPARAPPARG
SCHEMBL3004063 0.77 TRPA1 (0.45) OXER1CNR2CNR1KDM4ETRPA1
SCHEMBL13469394 0.76 CNR2 (0.56) CNR2CNR1KDM4EPPARAPPARG
SCHEMBL15291032 0.76 CNR2 (0.56) CNR2CNR1KDM4EPPARAPPARG
SCHEMBL13469404 0.76 CNR2 (0.56) CNR2CNR1KDM4EPPARAPPARG
SCHEMBL6941510 0.76 KDM4E (0.51) OXER1CNR2CNR1KDM4EPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028348-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS INC (US) 2026-01-29 US disclosed
US-20250333429-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS INC (US) 2025-10-30 US disclosed
US-12384808-B2 Modulators of TNF-α activity FORWARD THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
US-20240247014-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384808-B2 Modulators of TNF-α activity TNF, NFKBIA, TNFRSF1A OXER1 2708/4885CNR2 4641/4885CNR1 4501/4885
US-20250333429-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, NFKBIA, TNFRSF1A OXER1 2786/4885CNR2 4653/4885CNR1 4491/4885
US-20260028348-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, TNFRSF9 OXER1 365/4885CNR2 1067/4885CNR1 745/4885
US-20240247014-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, NFKBIA, TNFRSF1A OXER1 2786/4885CNR2 4653/4885CNR1 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.